Perspective Confidentiality Disclosure Reliability Courtesy
Yet again there is a lot of media noise about the possible impact of statins — drugs like simvastatin and Lipitor (atorvastatin) — on risk for prostate cancer. This time it results from a 15-year follow-up study of men at the Durham VA Medical Center in North Carolina.
Filed under: Management, Prevention | Tagged: statin | 4 Comments »
We have separately commented on a Swedish pilot study showing that men treated with captopril following radical prostatectomy had a significant reduction in risk of biochemical recurrence. Other reports today deal with:
The potential of contrast enhanced eMRI in diagnosis and monitoring
Whether we can better identify high-risk patients with localized disease for curative surgery
Early-stage patients and risk [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", contrast-enhanced eMRI, depression, hot flashes, mortality, surgery | No Comments »
A potentially important Swedish pilot study has shown that men treated with the old cardiovascular drug captopril (Capoten) following radical prostatectomy had a very significant reduction in biochemical recurrence over an average follow-up of 29 months compared to untreated patients.
Filed under: Management, Treatment | Tagged: captopril | No Comments »
Part B of today’s prostate cancer news update includes information about:
Screening behaviors of Afro-Caribbean men in Brooklyn, NY
Weight loss and prostate cancer risk
Potential of upgrading and upstaging of men with “favorable” prostate cancer on diagnosis
Effects of ADT on body lean and body fat mass
Salvage radiotherapy + androgen deprivation and toxic impact of treatment
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: ADT, Afro-Caribbean, body mass, salvage radiotherapy, screening, upgrading, upstaging, weight | No Comments »
There’s a lot of news today, so we will break it into two sections for reading convenience. In Part A, we deal with information about:
Physicial activity and prostate cancer risk
Vasectomy and prostate cancer risk
The use of surveillance and watchful waiting in men in Sweden
A modification to Walsh’s nerve-sparing radical prostatectomy
The risks of “multimodal” therapy in [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Prevention, Treatment, Uncategorized | Tagged: Add new tag, multimodal therapy, physical activity, radical prostatectomy, risk, surveillance, testosterone replacement, vasectomy | No Comments »
We are pleased to hear that Dr. Gerald Chodak has now been able to complete his totally video-based prostate disease web service. This has been a considerable “labor of love” on Dr. Chodak’s part, but it will be an immensely valuable contribution to prostate cancer education for those who learn faster and better by “seeing and [...]
Filed under: Uncategorized | No Comments »
Medscape has just published an extensive update on the ongoing Phase I/II clinical trial of MDV3100 an investigational androgen-receptor antagonist for use in the treatment of advanced prostate cancer.
Filed under: Drugs in development, Treatment | Tagged: MDV3100 | No Comments »
Many reader will already have seen or heard reports of the demise of the SELECT prostate cancer prevention trial. In other news today:
There is a recent review of trials of diet and dietary supplements
Further evidence supports the potential of surrogate markers for prostate cancer mortality
Saturation biopsies appear to overestimate the risk of prostate cancer
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: diet, supplements, biopsy, surrogate endpoint | No Comments »
It was dramatic: a 63% reduction in prostate cancer incidence in men who took selenium pills. Everyone took notice. Everyone talked. And men took loads of selenium.
Filed under: Uncategorized | No Comments »
Following an independent, initial review of the study data, the National Cancer Institute and the Southwest Oncology Group have stopped the 35,000-man SELECT study (Selenium and Vitamin E Cancer Prevention Trial). Apparently the supplements were not effective together or on their own in this four-arm trial.
Filed under: Management, Prevention | Tagged: Prevention, selenium, SELECT, vitamin E | No Comments »
